Benuvia Operations Drug Patent Portfolio
Benuvia Operations owns 1 orange book drug protected by 4 US patents Given below is the list of Benuvia Operations's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10265293 | Oral cannabinoid formulations | 06 Aug, 2028 | Active |
| US11253472 | Oral cannabinoid formulations | 06 Aug, 2028 | Active |
| US8222292 | Liquid cannabinoid formulations | 06 Aug, 2028 | Active |
| US9345771 | Oral cannabinoid formulations | 06 Aug, 2028 | Active |
Latest Legal Activities on Benuvia Operations's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Benuvia Operations.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 20 Nov, 2023 | US8222292 (Litigated) |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 21 Jul, 2022 | US10265293 |
|
Email Notification
Critical
| 20 Jul, 2022 | US10265293 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 20 Jul, 2022 | US10265293 |
|
Correspondence Address Change
Critical
| 19 Jul, 2022 | US10265293 |
|
Recordation of Patent Grant Mailed
Critical
| 22 Feb, 2022 | US11253472 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 22 Feb, 2022 | US11253472 |
|
Email Notification
Critical
| 03 Feb, 2022 | US11253472 |
|
Issue Notification Mailed
Critical
| 02 Feb, 2022 | US11253472 |
|
Application Is Considered Ready for Issue
Critical
| 14 Jan, 2022 | US11253472 |
| Dispatch to FDC | 14 Jan, 2022 | US11253472 |
|
Issue Fee Payment Verified
Critical
| 12 Jan, 2022 | US11253472 |
|
Issue Fee Payment Received
Critical
| 12 Jan, 2022 | US11253472 |
| Response to Reasons for Allowance | 12 Jan, 2022 | US11253472 |
|
Electronic Review
Critical
| 15 Oct, 2021 | US11253472 |
Benuvia Operations's Family Patents
Benuvia Operations Drug List
Given below is the complete list of Benuvia Operations's drugs and the patents protecting them.
1. Syndros
Syndros is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10265293 | Oral cannabinoid formulations |
06 Aug, 2028
(3 years from now)
| Active |
| US11253472 | Oral cannabinoid formulations |
06 Aug, 2028
(3 years from now)
| Active |
| US8222292 | Liquid cannabinoid formulations |
06 Aug, 2028
(3 years from now)
| Active |
| US9345771 | Oral cannabinoid formulations |
06 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Syndros's drug page